Skip to main
ANNX
ANNX logo

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annexon Inc. is poised for a positive outlook based on its clinical advancements and robust pipeline targeting complement-mediated disorders. The promising real-world evidence demonstrated by ANX005, showing a significant 10-point improvement in MRC sum score and enhanced health status in comparison to standard therapies, underlines the potential for breakthrough therapies within its portfolio. Additionally, the successful early completion of Phase 3 enrollment for ANX007 and its entry into the EMA's PRIME PDC pilot bolster the credibility of the company's innovative approach to vision preservation, further enhancing its competitive position in the biopharmaceutical sector.

Bears say

Annexon Inc faces significant risks that contribute to a negative outlook, particularly surrounding its lead product candidate, ANX005. The company's reliance on the successful completion of clinical studies, regulatory approval in both the US and EU, and the ability of ANX005 to meet peak commercial revenue expectations poses considerable uncertainties. Additionally, Annexon reported a substantial net loss of $49.2 million, reflecting ongoing financial challenges that may hinder its operational viability and strategic objectives.

Annexon, Inc (ANNX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annexon, Inc (ANNX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.